Kidney Transplantion Clinical Trial
— PRIDEOfficial title:
A Pilot Trial of the Effect of Dietary and Exercise Intervention on Insulin Resistance and Metabolic Parameters in De Novo Renal Transplant Recipients on Prograf (Tacrolimus)
The purpose of this trial is to investigate whether a combined dietary and exercise intervention, added to standard care, reduces the expected frequency of insulin resistance in renal (kidney) transplant recipients on tacrolimus.
| Status | Completed |
| Enrollment | 55 |
| Est. completion date | June 2010 |
| Est. primary completion date | June 2010 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Participants who has sufficiently recovered from surgery to tolerate an intensive exercise evaluation - Participants who have received a living-donor or cadaveric (from dead donor) renal transplant - Participants who has been initiated tacrolimus as first-line immunosuppressive agent - Participants who has given informed consent forms Exclusion Criteria: - Participants with significant disease or disability that prevents taking part in a diet or exercise regime (e.g. cardiac instability, including unstable angina [chest pain due to decreased oxygen being supplied to the heart] and/or other unstable disease, severe cognitive [mental functioning] impairment) - Participants with significant post-surgical complications that prevent participation in the exercise component of the study (e.g. wound dehiscence [pathologic process consisting of a partial or complete disruption of the layers of a surgical wound] or infection) - Participants with contraindications to maximal exercise testing or high-intensity progressive resistance training (e.g. proliferative diabetic or hypertensive retinopathy, un-repaired aneurysm, critical aortic stenosis, recurrent symptomatic hernias, New York Heart Association (NYHA) class-IV congestive heart failure) - Participants with non-ambulatory (mobility) status - Participants who require ongoing systemic immunosuppressive therapy for an indication other than renal transplant and this therapy is higher than that required for their kidney disease |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Janssen-Cilag Pty Ltd |
Australia,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Percentage of Participants With Insulin Resistance | Percentage of participants with insulin resistance as defined by a Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) greater than 1. HOMA uses fasting glucose and insulin (or C-peptide) to assess beta-cell function and IR. HOMA-IR is used to estimate insulin resistance. HOMA-IR is calculated by equation: HOMA-IR=fasting plasma insulin (milliunit [mU] per liter [L]) * fasting plasma glucose (millimole per liter [mmol per L]) divided by 22.5. | Week 24 | No |
| Secondary | Percentage of Participants With Impaired Fasting Glycaemia (IFG) | IFG is defined as a fasting venous plasma glucose concentration greater than or equal to 6.1 mmol per L but less than 7.0 mmol per L, together with a 2-hour plasma glucose concentration of less than 7.8 mmol per L. | Week 24 | No |
| Secondary | Percentage of Participants With Impaired Glucose Tolerance (IGT) | IGT is defined as fasting venous plasma glucose of less than 7.0 mmol per L, together with a 2-hour plasma glucose of greater than or equal to 7.8 mmol per L but less than 11.1 mmol per L. | Week 24 | No |
| Secondary | Percentage of Participants With Diabetes Mellitus (DM) | DM is defined as a fasting plasma glucose concentration greater than or equal to 7.0 mmol per L, or a 2-hour plasma glucose greater than or equal to 11.1 mmol per L. | Week 24 | No |
| Secondary | Beta Cell Function | HOMA-Beta is used to assess beta-cell function. HOMA-Beta is a measure of Beta-cell function (higher values present increased insulin secretion for a given glucose level). HOMA-Beta is calculated by the equation: HOMA-Beta=(20*FPI) divided by (FPG-3.5), where, FPI is fasting plasma insulin concentration (mU per L) and FPG is fasting plasma glucose concentration (mmol per L). | Baseline, Week 4, Week 12, and Week 24 | No |
| Secondary | Number of Participants With Acute Rejection, Graft Loss and Death | Acute rejection episodes are classified into: Spontaneously resolving - a rejection episode which is not treated with new or increased corticosteroid medication, antibodies or any other medication. Corticosteroid sensitive - a rejection episode, which is treated with new or increased corticosteroid medication only. Corticosteroid resistant - a rejection episode, which is not resolve following treatment with corticosteroids. Graft loss is defined as re-transplantation, nephrectomy, death or as dialysis ongoing at study end (or at withdrawal of the participants from the study). | Week 24 | No |
| Secondary | Body Mass Index (BMI) | BMI is a statistical measurement which compares a person's weight and height. Though it does not actually measure the percentage of body fat, it is used to estimate a healthy body weight based on participant's height. BMI is equal to weight divided by height square. Weight is measured in Kilogram and height is measured in meter. | Baseline, Week 4, Week 12 and Week 24 | No |
| Secondary | Bone Mineral Density | Bone mineral density is measured by Dual-Energy X-ray Absorptiometry (DEXA). | Baseline and Week 24 | No |
| Secondary | Waist to Hip Ratio (WHR) | WHR is performed using a standard medical measuring tape, with recordings documented in centimeters. Measurements will be compared against data from participating sites (where available) and against baseline. Measurement of hip circumference will be performed at the widest part of the buttocks. Measurement of the waist will be performed at the smaller circumference of the natural waist (usually just superior to the umbilicus). WHR is calculated by dividing the waist measurement by the hip measurement, and recorded to 2 decimal places. | Baseline, Week 4, Week 12 and Week 24 | No |
| Secondary | Body Composition: Percent Body Fat | Body fat will be assessed by DEXA scan. | Baseline and Week 24 | No |
| Secondary | Body Composition: Lean Mass, Bone Mass and Adjusted Weight | Body composition lean mass and bone mass will be assessed by DEXA scan. | Baseline and Week 24 | No |
| Secondary | Body Composition: T Score (Full Body) and Z Score (Full Body) | Body composition: T score (Full body) and Z score (full body) will be assessed by DEXA scan. | Baseline and Week 24 | No |
| Secondary | Blood Pressure: Systolic and Diastolic Pressure | Measurement of blood pressure will be performed by using a completely automated device consisting of an inflatable cuff and oscillatory detection system. Blood pressure will be taken supine, after 5 minutes of rest. | Baseline, Week 4, Week 12 and Week 24 | No |
| Secondary | Lipid Profile | In lipid profile total cholesterol, high-density lipoprotein (HDL) - cholesterol, low-density lipoprotein (LDL) - cholesterol and triglycerides levels will be evaluated. Measurement of the lipid profile will be performed in fasted state. | Baseline, Week 4, Week 12, and Week 24 | No |
| Secondary | Hemoglobin A, Glycosylated (HbA1c) | Measurement of the change in HbA1c will be performed in fasted state and in local laboratories. | Baseline, Week 4, Week 12 and Week 24 | No |
| Secondary | Estimated Glomerular Filtration Rate (eGFR) | The eGFR is calculated by Modification of Diet in Renal Disease (MDRD) equation is recommended by Kidney Health Australia as the calculation of choice for predicting GFR. According to MDRD equation eGFR is equal to 186*(Serum creatinine/0.095)^-1.154*age^0.203*race*sex, where the unit of serum creatinine is micro mole per L, the age is in years; race is 1.212 if African American, or 1 otherwise; and sex equals 1 if male, and 0.742 if female. eGFR will be compared against baseline. | Baseline, Week 4, Week 12 and Week 24 | No |
| Secondary | 36-Item Short-Form (SF-36) Score - Health Survey | This SF-36 standardize survey evaluates participants health by 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as Physical Component Scores (PCS) and Mental Component Scores (MCS). The score for a section is an average of the individual question scores, which are scaled 0 to 100, Higher score indicates highest level of functioning. | Baseline, Week 12 and Week 24 | No |
| Secondary | Percentage of Participants who will be Sedentary, Insufficiently Active and Sufficiently Active According to Active Australia Survey (AAS) | AAS is used for physical activity surveillance and it consists of following categories: 'sedentary' - people who are doing no activity at all; 'sufficiently active'- participation in at least 150 minutes per week; 'insufficiently active'- the remainder participants whose participation is not enough to obtain a health benefit. | Week 4, Week 12 and Week 24 | No |
| Secondary | Percentage of Participants Compliant With Both Dietary Advice and Exercise Program and Non-Compliant With Dietary Advice or Exercise Program | Compliance with dietary advice will be measured on a categorical scale ranging from 0=no compliance to 10=full compliance. Compliance with exercise program is measured as the completion of 3 exercise sessions per week for the 6-month period. | Week 4, Week 12 and Week 24 | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04932876 -
The Response of the Immune System of Patients With End Stage Kidney Disease on Dialysis and Kidney Transplant Recipients Vaccinated for COVID-19
|